David Lucchino

David L. Lucchino is co-founder, president and CEO of Frequency Therapeutics (Nasdaq:FREQ)[2][3]

David L. Lucchino
Born (1969-02-16) February 16, 1969
Pittsburgh, Pennsylvania
Alma materDenison University

Syracuse University

Massachusetts Institute of Technology
Years active1991 to present
TitleCo-founder, president and CEO, Frequency Therapeutics[1]
Board member ofMassachusetts Biotechnology Council Multiple Myeloma Research Foundation
Parent(s)Frank J. Lucchino

Personal

A Pittsburgh native, Lucchino graduated in 1987 from Central Catholic High School.[4] He is the son of Judge Frank Lucchino and is the nephew of former Boston Red Sox president Larry Lucchino.[5][6]

Lucchino obtained an MBA degree from MIT Sloan School of Management as an Alfred P. Sloan Fellow.[7] Lucchino also holds a Master of Science degree from Syracuse University and a Bachelor of Arts degree from Denison University.[8][9]

Career

In 2006, while earning his MBA at MIT's Sloan School of Management, Lucchino was selected by Dr. Robert S. Langer to join a team to create implant surface technology that prevents blood clotting and infection. The team transitioned into the company Semprus BioSciences.[10] Lucchino secured $28.5 million in venture capital financing and $5.4 million in federal funding for the company.[11]

Lucchino is the co-founder, CEO and president of Frequency Therapeutics since November 2014, first serving as chairman, and subsequently taking on the president and CEO roles alongside co-founders biomedical engineer Jeffrey Karp and Langer.[12]

Activities

He was a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the national trade association representing the US medical device industry, from 2010 to 2013. He also serves as a director of Lipella Pharmaceuticals Inc.[13] In 2013, Lucchino joined the board of the Multiple Myeloma Research Foundation.[14]

He is a former member of the Board of Governors for the Sloan Fellows program.[15]

In March 2018, Lucchino began a two-year term as chairman of the Massachusetts Biotechnology Council.[16] Lucchino earlier was an elected member of the Board of Directors of the Massachusetts Biotechnology Council. He is a Trustee of Mt. Auburn Hospital, a 200-bed Harvard Medical School facility. He is also on the Audit Committee for CareGroup: the parent organization of Mt. Auburn, Beth Israel Deaconess Medical Center and The New England Baptist Hospital.[17]

References
  1. Mamula, Kris (February 28, 2020). "New commercial lab space in Pittsburgh could exceed 700,000 square feet in a few years". Pittsburgh Post-Gazette.
  2. McLean, Will (2018-03-09). "Toward a true cure for hearing impairment". Science. 359 (6380): 1113.3–1113. doi:10.1126/science.aat0966. ISSN 0036-8075. PMID 29590039.
  3. "A Glimpse Into David Lucchino, Cofounder And CEO Of Frequency Therapeutics". Life Science Leader. 2020-09-21. Retrieved 2020-10-16.
  4. "David Lucchino Career Stats Leagues Statistics & History Baseball-Reference.com". Baseball-Reference.com. Retrieved 2018-02-09.
  5. "Kimberly Kissam, David Lucchino". The New York Times. 2007-05-27. ISSN 0362-4331. Retrieved 2018-02-09.
  6. "How We Met: The Red Sox Fans - Boston.com". archive.boston.com. Retrieved 2018-02-09.
  7. "A degree of choice for the older and wiser student". Financial Times. 2012-03-19. Retrieved 2018-02-09.
  8. College, Babson. "Lucchino Joins Babson Board". Retrieved 2018-02-09.
  9. "Boston Red Sox - Ankle fracture sends Pesky home - The Boston Globe". archive.boston.com. Retrieved 2018-02-09.
  10. "Semprus Biosciences, launched in MIT lab, finds buyer for medical device technology - The Boston Globe". BostonGlobe.com. Retrieved 2018-09-11.
  11. Kirsner, Scott (2010-12-13). "Semprus BioSciences lands another $18m". Boston.com. Retrieved 2018-09-11.
  12. "Xconomy: Frequency, Led by MIT's Langer, Aims to Fight Hearing Loss With Drugs". Xconomy. 2017-01-05. Retrieved 2018-09-11.
  13. "Board". lipella.com. Retrieved 2018-09-11.
  14. "David L. Lucchino - Multiple Myeloma Research Foundation". Multiple Myeloma Research Foundation. 2014-09-09. Retrieved 2018-02-09.
  15. "David L. Lucchino, Semprus BioSciences Ceo & Co-founder, Elected to Massbio Board at Annual Meeting | Evaluate". evaluategroup.com. Retrieved 2018-02-09.
  16. Max Stendahl (February 26, 2018). "Biotech startup CEO David Lucchino to helm MassBio board". Boston Business Journal. Retrieved 2018-09-11.
  17. "David Lucchino - DeviceTalks". DeviceTalks. Retrieved 2018-02-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.